Cliff Asness's AGIO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 91,635 shares of Agios Pharmaceuticals, Inc. (AGIO) worth $3.61 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in AGIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2024, adding 104,978 shares. Largest reduction occurred in Q1 2017, reducing 111,539 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Agios Pharmaceuticals (AGIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Agios Pharmaceuticals (AGIO) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +14,000 | New Buy | 14,000 | $61.36 |
| Q4 2014 | -11,300 | Reduce 80.71% | 2,700 | $112.22 |
| Q1 2015 | +35,400 | Add 1311.11% | 38,100 | $94.28 |
| Q2 2015 | +7,161 | Add 18.80% | 45,261 | $111.13 |
| Q3 2015 | -21,734 | Reduce 48.02% | 23,527 | $70.60 |
| Q4 2015 | -3,073 | Reduce 13.06% | 20,454 | $64.93 |
| Q1 2016 | -20,454 | Sold Out | 20,454 | $0.00 |
| Q2 2016 | +35,308 | New Buy | 35,308 | $41.89 |
| Q3 2016 | +97,998 | Add 277.55% | 133,306 | $52.82 |
| Q4 2016 | -10,003 | Reduce 7.50% | 123,303 | $41.73 |
| Q1 2017 | -111,539 | Reduce 90.46% | 11,764 | $58.40 |
| Q2 2017 | -11,764 | Sold Out | 11,764 | $0.00 |
| Q2 2018 | +12,811 | New Buy | 12,811 | $84.22 |
| Q3 2018 | -402 | Reduce 3.14% | 12,409 | $77.12 |
| Q4 2018 | -7,017 | Reduce 56.55% | 5,392 | $46.18 |
| Q2 2019 | -5,392 | Sold Out | 5,392 | $0.00 |
| Q2 2021 | +7,185 | New Buy | 7,185 | $53.31 |
| Q3 2021 | +27,346 | Add 380.60% | 34,531 | $46.16 |
| Q4 2021 | -34,531 | Sold Out | 34,531 | $0.00 |
| Q2 2023 | +7,717 | New Buy | 7,717 | $28.16 |
| Q3 2023 | -7,717 | Sold Out | 7,717 | $0.00 |
| Q1 2024 | +11,184 | New Buy | 11,184 | $29.23 |
| Q2 2024 | +21,980 | Add 196.53% | 33,164 | $43.12 |
| Q3 2024 | +104,978 | Add 316.54% | 138,142 | $44.43 |
| Q4 2024 | -107,278 | Reduce 77.66% | 30,864 | $32.86 |
| Q1 2025 | +20,625 | Add 66.83% | 51,489 | $29.10 |
| Q2 2025 | +45,407 | Add 88.19% | 96,896 | $33.17 |
| Q3 2025 | -5,261 | Reduce 5.43% | 91,635 | $39.35 |
Cliff Asness's Agios Pharmaceuticals Investment FAQs
Cliff Asness first purchased Agios Pharmaceuticals, Inc. (AGIO) in Q3 2014, acquiring 14,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Agios Pharmaceuticals, Inc. (AGIO) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Agios Pharmaceuticals, Inc. (AGIO) was in Q3 2024, adding 138,142 shares worth $6.14 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 91,635 shares of Agios Pharmaceuticals, Inc. (AGIO), valued at approximately $3.61 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Agios Pharmaceuticals, Inc. (AGIO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Agios Pharmaceuticals, Inc. (AGIO) was 138,142 shares, as reported at the end of Q3 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.